Version 1
: Received: 30 March 2024 / Approved: 1 April 2024 / Online: 2 April 2024 (07:37:25 CEST)
How to cite:
Formenti, P.; Umbrello, M.; Pignataro, M.; Sabbatini, G.; Dottorini, L.; Gotti, M.; Brenna, G.; Menozzi, A.; Terranova, G.; Galimberti, A.; Pezzi, A. Current Perspectives on Oxycodone/Naloxone Prolonged Release for Managing Severe Cancer Pain: A Comprehensive Update of Literature. Preprints2024, 2024040150. https://doi.org/10.20944/preprints202404.0150.v1
Formenti, P.; Umbrello, M.; Pignataro, M.; Sabbatini, G.; Dottorini, L.; Gotti, M.; Brenna, G.; Menozzi, A.; Terranova, G.; Galimberti, A.; Pezzi, A. Current Perspectives on Oxycodone/Naloxone Prolonged Release for Managing Severe Cancer Pain: A Comprehensive Update of Literature. Preprints 2024, 2024040150. https://doi.org/10.20944/preprints202404.0150.v1
Formenti, P.; Umbrello, M.; Pignataro, M.; Sabbatini, G.; Dottorini, L.; Gotti, M.; Brenna, G.; Menozzi, A.; Terranova, G.; Galimberti, A.; Pezzi, A. Current Perspectives on Oxycodone/Naloxone Prolonged Release for Managing Severe Cancer Pain: A Comprehensive Update of Literature. Preprints2024, 2024040150. https://doi.org/10.20944/preprints202404.0150.v1
APA Style
Formenti, P., Umbrello, M., Pignataro, M., Sabbatini, G., Dottorini, L., Gotti, M., Brenna, G., Menozzi, A., Terranova, G., Galimberti, A., & Pezzi, A. (2024). Current Perspectives on Oxycodone/Naloxone Prolonged Release for Managing Severe Cancer Pain: A Comprehensive Update of Literature. Preprints. https://doi.org/10.20944/preprints202404.0150.v1
Chicago/Turabian Style
Formenti, P., Andrea Galimberti and Angelo Pezzi. 2024 "Current Perspectives on Oxycodone/Naloxone Prolonged Release for Managing Severe Cancer Pain: A Comprehensive Update of Literature" Preprints. https://doi.org/10.20944/preprints202404.0150.v1
Abstract
Severe cancer pain significantly diminishes patients' quality of life, leading to increased reliance on caregivers. Although opioid analgesics are effective, they may induce opioid-induced bowel dysfunction (OIBD) with symptoms such as nausea, vomiting, drowsiness, and constipation. While controlled-release oxycodone is a viable option, its prolonged use can lead to opi-oid-induced constipation (OIC). Addressing this, a relative novel formulation - a fixed 2:1 ratio of oxycodone and naloxone in prolonged release - aims to provide analgesia while alleviating OIC. This review critically assesses the evidence on the efficacy, safety, and patient experience of ox-ycodone/naloxone prolonged release in managing severe cancer pain, emphasizing the necessity for a targeted approach in this patient population.
Keywords
severe cancer pain; oxycodone/naloxone; pain management
Subject
Medicine and Pharmacology, Anesthesiology and Pain Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
